knowledge -WSS

knowledge

author：fashion 2025-08-19 15:02:21 - browse：72924

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： As obesity drug market grows, telehealth companies court payers

WSS

CDC says it’s too soon to assess risk posed by Covid subvariant

Pharma showers House GOP doctor with campaign cash

CDC says it’s too soon to assess risk posed by Covid subvariant

'Null' research findings aren't empty of meaning. Let's publish them

FDA greenlights medical device to combat bladder issues

FDA scientists endorse Pfizer/BioNTech Covid

entertainment

knowledge

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

DeSantis wants to import drugs. Biden’s FDA blasted his plan

23andMe had bad news about my health. I wish a person had delivered it

FDA approves Sage Therapeutics’ rapid

Sports medicine is finally prioritizing gender equality

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Apple is now the first public company to be valued at $3 trillion

Former Pear Therapeutics executives start new VC firm

ChatGPT in medicine: STAT answers readers' burning questions

Former Pear Therapeutics executives start new VC firm

hotspot

FDA greenlights medical device to combat bladder issues

Group behind ProMed defends move to subscription

Alnylam reports growth in sales of rare disease treatments

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

'Null' research findings aren't empty of meaning. Let's publish them

FDA approves Sage Therapeutics’ rapid

focus

Wikipedia

Wikipedia

focus